December 12, 2023 C-Path’s RDCA-DAP Program and PicnicHealth Announce Data Collaboration to Accelerate Rare Disease Research TUCSON, Ariz., December 12, 2023 – Critical Path Institute (C-Path), a leader in advancing rare disease research, is pleased to
November 29, 2023 C-Path’s Translational Therapeutics Accelerator and Celdara Medical Announce Pipeline-focused MOU TUCSON, Ariz. and LEBANON, N.H., November 29, 2023 — Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator
November 9, 2023 C-Path’s Pioneering Neuroscience Workshop Transforms the Landscape of Neurological Disorder Therapies TUCSON, Ariz., Nov. 9, 2023 – Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publica
November 7, 2023 C-Path’s T1D Consortium New-onset Article Published in The Lancet Diabetes and Endocrinology ype 1 Diabetes Consortium, along with external collaborators from Cardiff University and the University of Alberta, today announce
October 26, 2023 C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement TUCSON, Ariz., October 26, 2023 — Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI), a leading
October 25, 2023 C-Path Announces Significant Expansion in Neonatal RWD Project Details of the expansion will be a highlight of the Institute’s Scientific Breakthrough Summit Oct. 26-27 in D.C. TUCSON, Ariz.,
October 3, 2023 C-Path Rare and Orphan Disease Conference Highlights Unprecedented Collaborations and Breakthroughs in Rare Disease Research TUCSON, Ariz., October 3, 2023 — The Critical Path Institute (C-Path) held its highly anticipated Rare and Orphan Disease Confer
September 18, 2023 C-Path and EATRIS Join Forces with New Collaboration Agreement AMSTERDAM and TUCSON, Ariz., September 18, 2023 — Critical Path Institute (C-Path) and EATRIS (the European Research Infrastruct
September 12, 2023 C-Path’s Rare Disease Clinical Outcome Assessment Consortium Launches Rare Disease COA Resource The Rare Disease COA Resource aims to simplify COA selection for use in rare disease drug development. TUCSON, Ariz., Septe
Postdoc Ruby Abrams Shares Professional Development Opportunities Provided by C-Path Critical Path Institute is dedicated to advancing careers in the medical development and regulatory science industries. We are hap